CDPPB

Из Википедије, слободне енциклопедије
CDPPB
CDPPB structure.png
IUPAC ime
3-ciano-N-(1,3-difenil-1H-pirazol-5-il)benzamid
Identifikatori
CAS broj 781652-57-1 ДаY
ATC kod none
PubChem CID 11245456
IUPHAR/BPS 1422
Hemijski podaci
Formula C23H18N4O
Molarna masa 366,414 g/mol
  (verify)

CDPPB je lek koji se koristi u naučnim istraživanjima. On deluje kao pozitivni alosterni modulator koji je selektivan za metabotropni glutamatni receptor mGluR5.[1][2][3] On ima antipsihotičke efekte u životinjskim modelima.[4] and mGluR5 Modulatori se istražuju kao potencijalni lekovi za tretman šizofrenije,[5] i drugih bolesti.[6][7]

Reference[уреди]

  1. Lindsley CW, Wisnoski DD, Leister WH, O'brien JA, Lemaire W, Williams DL, Burno M, Sur C, Kinney GG, Pettibone DJ, Tiller PR, Smith S, Duggan ME, Hartman GD, Conn PJ, Huff JR (2004). „Discovery of positive allosteric modulators for the metabotropic glutamate receptor subtype 5 from a series of N-(1,3-diphenyl-1H- pyrazol-5-yl)benzamides that potentiate receptor function in vivo”. Journal of Medicinal Chemistry. 47 (24): 5825—8. doi:10.1021/jm049400d. PMID 15537338. 
  2. de Paulis T, Hemstapat K, Chen Y, Zhang Y, Saleh S, Alagille D, Baldwin RM, Tamagnan GD, Conn PJ (2006). „Substituent effects of N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamides on positive allosteric modulation of the metabotropic glutamate-5 receptor in rat cortical astrocytes”. Journal of Medicinal Chemistry. 49 (11): 3332—44. doi:10.1021/jm051252j. PMID 16722652. 
  3. Chen Y, Nong Y, Goudet C, Hemstapat K, de Paulis T, Pin JP, Conn PJ (2007). „Interaction of novel positive allosteric modulators of metabotropic glutamate receptor 5 with the negative allosteric antagonist site is required for potentiation of receptor responses”. Molecular Pharmacology. 71 (5): 1389—98. doi:10.1124/mol.106.032425. PMID 17303702. 
  4. Kinney GG, O'Brien JA, Lemaire W, Burno M, Bickel DJ, Clements MK, Chen TB, Wisnoski DD, Lindsley CW, Tiller PR, Smith S, Jacobson MA, Sur C, Duggan ME, Pettibone DJ, Conn PJ, Williams DL (2005). „A novel selective positive allosteric modulator of metabotropic glutamate receptor subtype 5 has in vivo activity and antipsychotic-like effects in rat behavioral models”. The Journal of Pharmacology and Experimental Therapeutics. 313 (1): 199—206. doi:10.1124/jpet.104.079244. PMID 15608073. 
  5. Lindsley CW, Shipe WD, Wolkenberg SE, Theberge CR, Williams DL, Sur C, Kinney GG (2006). „Progress towards validating the NMDA receptor hypofunction hypothesis of schizophrenia”. Current Topics in Medicinal Chemistry. 6 (8): 771—85. doi:10.2174/156802606777057599. PMID 16719816. 
  6. Lecourtier L, Homayoun H, Tamagnan G, Moghaddam B (2007). „Positive allosteric modulation of metabotropic glutamate 5 (mGlu5) receptors reverses N-Methyl-D-aspartate antagonist-induced alteration of neuronal firing in prefrontal cortex”. Biological Psychiatry. 62 (7): 739—46. doi:10.1016/j.biopsych.2006.12.003. PMC 2910402Слободан приступ. PMID 17511968. 
  7. Gass JT, Olive MF (2009). „Positive allosteric modulation of mGluR5 receptors facilitates extinction of a cocaine contextual memory”. Biological Psychiatry. 65 (8): 717—20. doi:10.1016/j.biopsych.2008.11.001. PMC 2870714Слободан приступ. PMID 19100966. 

Spoljašnje veze[уреди]